Welcome to our blog page. On this page we want to share our market access expertise build up over the past decades in the BeNeLux.
We wish you a lot of reading pleasure. If you have any questions or comments, you can always contact us.
How to prove the concerned price if the specialty is not yet produced? What is the value of a proven pricing structure if the price is downsized over time? Lets discuss to overcome this bottleneck.
You dive into a simulation model and at first everything seems flawless. But with each adjustment the risk of flaws creeping into the programming.
The 'ICER' is a well-known measure to assess the extra cost to invest to win one QALY. In Belgium, unofficially 35 000 € / QALY gained is often applied as benchmark, the 'willingness to pay' (WTP). But does the payer invest the budget in function of the potential medical need or not ?
